首页> 外文期刊>Journal of Labelled Compounds and Radiopharmaceuticals >Conception, realization and qualification of a radioactive clean room lab facility dedicated to the synthesis of radiolabeled API for human ADME studies
【24h】

Conception, realization and qualification of a radioactive clean room lab facility dedicated to the synthesis of radiolabeled API for human ADME studies

机译:致力于合成人类Adme研究的放射性洁净室实验室设施的概念,实现和资格

获取原文
获取原文并翻译 | 示例
       

摘要

The human absorption, distribution, metabolism and elimination study administering radiolabeled drugs to human volunteers is an important clinical study in the development program of new drug candidates. The manufacture of radiolabeled Active Pharmaceutical Ingredients is covered by national drug laws and may come within the scope of regulatory GMP requirements. Additionally, authorities may request an appropriate environmental zoning to minimize the risk of microbiological contaminations particularly during the synthesis of radiolabeled Active Pharmaceutical Ingredients intended for parenteral application. Thus, a radioactive clean room lab facility in line with both GMP and radiation safety regulations was installed and the environmental zoning validated by appropriate testing of technical parameters and microbial and particle monitoring. The considerations detailed in this paper cover only GMP aspects related to the synthesis of radioactive drug substance. The subsequent, final formulation step in the overall process for manufacturing of radioactive drug product for any kind of administration is not within the scope of this paper. Under these qualified and controlled environmental conditions, we are now in a position to provide radiolabeled drug substances for all kinds of drug administration including both po and iv.
机译:人类吸收,分布,代谢和消除研究向人类志愿者施用放射性标记的药物是新毒品候选人发展计划中的重要临床研究。放射性标记活性药物成分的制造被国家毒品法所涵盖,可能在监管GMP要求范围内。此外,当局可以要求适当的环境分区,以最小化微生物污染的风险,特别是在合成肠胃外应用的放射性标记的活性药物成分期间。因此,安装了符合GMP和辐射安全法规的放射性洁净室实验室设施,并通过适当的技术参数和微生物和微粒监测进行验证的环境分区。本文详述的考虑因素仅涵盖与放射性药物合成相关的GMP方面。随后的最终制剂在用于任何施用的放射性药物制造总体过程中的总体方法不在本文的范围内。在这些合格和受控的环境条件下,我们现在可以提供用于各种药物管理的放射性标记药物,包括PO和IV。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号